I/O en­thu­si­ast Servi­er signs up for an $807M, sec­ond wave PD-1 de­vel­op­ment deal with Sor­ren­to

Sor­ren­to Ther­a­peu­tics, which is close­ly aligned with Patrick Soon-Sh­iong’s net­work of biotech com­pa­nies, has struck a deal to part­ner with France’s Servi­er on its PD-1 check­point pro­gram for STI-A1110.

Servi­er is hand­ing over a $27.5 mil­lion up­front to Sor­ren­to $SRNE in the deal while putting $780 mil­lion on the ta­ble for a full slate of mile­stones.

For Servi­er, it’s a chance to start work on its own in-house com­bi­na­tion drugs for blood can­cers as well as sol­id tu­mors. Servi­er has al­so been work­ing on CAR-T, adapt­ing T-cells in­to can­cer ther­a­pies. And while it’s well be­hind the pi­o­neers in both check­point in­hibitors – with three ap­proved for use – and CAR-T, the com­pa­ny still sees a sig­nif­i­cant niche fu­ture for it­self in im­muno-on­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.